Douglas E. Brough

Precigen (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index4.6kcitations82works4.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(41), Viral Infectious Diseases and Gene Expression in Insects(22), Hearing, Cochlea, Tinnitus, Genetics(17), CAR-T cell therapy research(12), Viral gastroenteritis research and epidemiology(11)

Publications82 total

PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer
Cancer Immunology Immunotherapy·2025· 5 citedOpen Access
PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial
The Lancet Respiratory Medicine·2025· 14 cited
232 Non-viral engineered next generation CD19 UltraCAR-T with membrane bound IL-15 (mbIL15) and PD-1 blockade preserves stem cell memory/naïve phenotype and enhances anti-tumor efficacy
Regular and Young Investigator Award Abstracts·2024Open Access
PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients.
Journal of Clinical Oncology·2024· 4 cited
Abstract 1193: Peripheral immune analyses from phase I trial of HPV vaccine PRGN-2009 in combination with bintrafusp alfa in patients with HPV-associated cancers
Cancer Research·2024
The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis
Science Translational Medicine·2023· 24 citedOpen Access
Impaired Regulation by IL-35 in Systemic Sclerosis
International Journal of Molecular Sciences·2023· 7 citedOpen Access
Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C).
Journal of Clinical Oncology·2023· 9 cited
Abstract 1791: Next generation UltraCAR-T® cells with intrinsic checkpoint inhibition and overnight manufacturing overcome suppressive tumor microenvironment leading to sustained antitumor activity
Cancer Research·2023· 1 cited
The immunoregulatory role of IL‐35 in patients with interstitial lung disease
Immunology·2022· 11 cited
Abstract 2821: Incorporation of intrinsic checkpoint blockade enhances functionality of multigenic autologous UltraCAR-T® cells manufactured using non-viral gene delivery and rapid manufacturing process
Cancer Research·2022
Improving Control of Gene Therapy-Based Neurotrophin Delivery for Inner Ear Applications
Frontiers in Bioengineering and Biotechnology·2022· 6 citedOpen Access
Preclinical Evaluation of Prgn-3007, a Non-Viral, Multigenic, Autologous ROR1 Ultracar-T ® Therapy with Novel Mechanism of Intrinsic PD-1 Blockade for Treatment of Hematological and Solid Cancers
Blood·2021· 5 cited
483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers
Regular and Young Investigator Award Abstracts·2021· 3 citedOpen Access
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
npj Vaccines·2021· 12 citedOpen Access
First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).
Journal of Clinical Oncology·2021· 3 cited
Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
JCI Insight·2021· 23 citedOpen Access
Anti-tumor efficacy and immune responses induced by a novel therapeutic HPV-specific gorilla adenovirus off-the-shelf immunotherapeutic (PRGN-2009)
The Journal of Immunology·2020· 3 cited
A New Gorilla Adenoviral Vector with Natural Lung Tropism Avoids Liver Toxicity and Is Amenable to Capsid Engineering and Vector Retargeting
Journal of Virology·2020· 14 citedOpen Access
Hearing Preservation Following Repeated Adenovector Delivery
The Anatomical Record·2020· 8 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Hinrich Staecker(11), Imre Kovesdi(10), Damodar Ettyreddy(9), Mark Praetorius(8), Jason G. Gall(7), C. Richter King(6), Kim Baker(5), Thomas J. Wickham(4), Joseph T. Bruder(4), Marvin J. Grubman(4), Christopher Schutta(4), José Barrera(4), John G. Neilan(4), Bryan T. Butman(4), David A. Brake(4), Chi Hsu(4), Peter K. Plinkert(4), Daniel F. Klessig(4), Peter W. Roelvink(3), Alena Lizonová(3)